Pluristem Therapeutics, Inc. is a biotechnology company that develops cell therapy products to treat severe blood, cardiovascular, autoimmune, and other disorders. Cell therapy is a technology that relies on replacing diseased or dysfunctional cells with healthy, functioning ones.
The Company’s first planned product, PLX-I, is intended to resolve the global shortage of matched tissue for bone marrow transplantation. PLX II is being developed as a personalized product for patients in need of a bone marrow transplant who have available autologous umbilical cord blood. Pluristem believes their future products will participate in the approximate $30 billion therapeutic and re...